KeyBanc Reiterates Sector Weight Rating on Mesa Laboratories (MLAB) Following 'Best Results in Years'

KeyBanc analyst Paul Knight reiterated a Sector Weight rating on Mesa Laboratories (NASDAQ: MLAB).

The analyst commented: "Best Results in Years and Preparing Balance Sheet for Consolidation; While MLAB had easy comparisons, its organic growth of 13.2% in the quarter was its best result since COVID-driven 2022. The Company posted a top- and bottom-line beat, and while mid-term growth may only be +MSD, three of its four key business units have clear momentum and Clinical Genomics (Agena diagnostics) has stabilized. Additionally, MLAB has $30M of purchasing capacity and its EV/EBITDA should allow it to accelerate its consolidation strategy later this calendar year. We release a revised model to reflect fiscal 3Q25 results and are also raising our go-forward revenue estimates."

For an analyst ratings summary and ratings history on Mesa Laboratories click here. For more ratings news on Mesa Laboratories click here.

Shares of Mesa Laboratories closed at $137.27 yesterday.

You May Also Be Interested In

• JPMorgan Downgrades ASX Limited (ASX:AU) (ASXFY) to Neutral
• Apple In Coming Months To Launch Suite Of AI Tools In China-sources - Reuters
• Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS) Tops Q2 EPS by 24c